MedPacto

메드팩토 · 235980

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$86.1M (₩118.8B)

Overview

MedPacto is a South Korean biotech company that develops new drugs aimed at treating hard-to-cure cancers and chronic diseases, using advanced genomic analysis to identify drug targets and biomarkers that help tailor treatments to individual patients.

Its drug candidates, including small-molecule compounds, antibodies, and Fc-fusion proteins, are designed for use in clinical and therapeutic settings. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company's research approach centers on combining genomic sequencing and bioinformatics tools with in-house animal-model testing to validate drug candidates.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$2.8M

Operating profit · FY2025

−US$10.2M

Loss narrowed

Net income · FY2025

−US$9.3M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$0(₩0)	US$0(₩0)	US$2.8M(₩3.9B)
Operating profit	−US$20.8M(−₩28.8B)	−US$15.8M(−₩21.8B)	−US$10.2M(−₩14B)
Net income	−US$25.6M(−₩35.3B)	−US$14.6M(−₩20.1B)	−US$9.3M(−₩12.8B)

Revenue

FY2023US$0
FY2024US$0
FY2025US$2.8M

Operating profit

FY2023−US$20.8M
FY2024−US$15.8M
FY2025−US$10.2M

Net income

FY2023−US$25.6M
FY2024−US$14.6M
FY2025−US$9.3M

Key ratios (FY2025)

ROE

-27.9%

Debt/Eq

5.8%

Op. margin

-359.6%

Net margin

-328.6%

Rev. YoY

N/A (see filing)

Why it matters

MedPacto was spun off from Terazen Etex, a KOSDAQ-listed precision-medicine and genomics company, when its drug-research division was established as an independent entity.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?